Lifesci Capital Analysts Lift Earnings Estimates for Savara

Key Points

• Lifesci Capital raised its Q2 2026 EPS estimate for Savara to ($0.12) from ($0.13) and trimmed its FY2026 loss forecast to ($0.48), signaling a slight improvement in near-term expectations.
• Savara reported quarterly EPS of ($0.13), missing the consensus estimate of ($0.12) by $0.01.
• Analysts hold a Moderate Buy consensus on SVRA with an average price target of $9.00, while the stock trades near $5 and has a market cap of about $1.05 billion.

Savara Inc. (NASDAQ:SVRA - Free Report) - Stock analysts at Lifesci Capital upped their Q2 2026 earnings per share estimates for Savara in a report released on Sunday, March 15th. Lifesci Capital analyst F. Brisebois now forecasts that the company will post earnings of ($0.12) per share for the quarter, up from their prior estimate of ($0.13). The consensus estimate for Savara's current full-year earnings is ($0.45) per share. Lifesci Capital also issued estimates for Savara's FY2026 earnings at ($0.48) EPS.

Savara (NASDAQ:SVRA - Get Free Report) last issued its quarterly earnings results on Friday, March 13th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01).

A number of other research analysts also recently commented on SVRA. HC Wainwright reiterated a "buy" rating on shares of Savara in a report on Monday. Oppenheimer set a $10.00 price target on Savara in a report on Tuesday, December 23rd. Wall Street Zen lowered shares of Savara from a "hold" rating to a "sell" rating in a research note on Saturday. Wells Fargo & Company raised their price objective on shares of Savara from $7.00 to $9.00 and gave the stock an "overweight" rating in a report on Thursday, December 18th. Finally, Guggenheim restated a "buy" rating on shares of Savara in a research report on Tuesday, December 23rd. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $9.00.

Savara Price Performance

Shares of SVRA opened at $5.15 on Wednesday. The company has a current ratio of 11.85, a quick ratio of 7.65 and a debt-to-equity ratio of 0.15. The firm's fifty day simple moving average is $5.65 and its 200-day simple moving average is $4.99. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of -9.72 and a beta of 0.31. Savara has a twelve month low of $1.89 and a twelve month high of $7.01.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Prudential Financial Inc. acquired a new position in Savara in the 2nd quarter valued at $30,000. BNP Paribas Financial Markets lifted its position in Savara by 52.3% during the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company's stock worth $31,000 after buying an additional 4,626 shares during the period. Brevan Howard Capital Management LP acquired a new position in shares of Savara during the 2nd quarter valued at about $33,000. Russell Investments Group Ltd. lifted its holdings in shares of Savara by 930.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company's stock worth $37,000 after acquiring an additional 9,463 shares during the period. Finally, Quadrature Capital Ltd purchased a new stake in Savara in the second quarter valued at approximately $42,000. Institutional investors and hedge funds own 87.93% of the company's stock.

Key Headlines Impacting Savara

Here are the key news stories impacting Savara this week:

• Positive Sentiment: Lifesci Capital raised its Q2 2026 EPS forecast slightly (from ($0.13) to ($0.12)) and trimmed FY2026 loss expectations marginally (to ($0.48) from ($0.49)), signaling a small improvement in near-term outlook. MarketBeat SVRA
• Positive Sentiment: HC Wainwright maintained a "Buy" rating on SVRA, which supports investor demand and suggests confidence in Savara’s longer-term commercial potential despite model changes. MarketBeat SVRA
• Neutral Sentiment: HC Wainwright published detailed quarterly cadence estimates for 2026 (Q1–Q4) and multi-year projections that give investors updated milestones to watch, but these are expectations rather than new company results. MarketBeat SVRA
• Negative Sentiment: HC Wainwright cut FY2026 EPS to ($0.49) from ($0.39), increasing the near-term loss outlook and likely weighing on the stock as investors reassess cash runway and commercialization timing. MarketBeat SVRA
• Negative Sentiment: HC Wainwright lowered FY2027 and FY2028 forecasts (FY2027 to ($0.28) from ($0.16); FY2028 to $0.02 from $0.13), and also trimmed FY2029/FY2030 upside — these pushes out and reduce expected profitability, pressuring valuation that had factored in stronger long-term growth. MarketBeat SVRA

About Savara

Savara Inc NASDAQ: SVRA is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company's lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.